ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research

from Applied Clinical Trials · host Applied Clinical Trials

In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from Novo Nordisk’s oral semaglutide program, and review Eli Lilly’s promising Phase II results for a novel amylin receptor agonist.

Episode metadata supplied by the publisher feed · Published Nov 7, 2025

Embed this episode

Attribution link and audio player

Ready to play

ACT Brief: Designing Feasible Protocols and Breakthroughs in Obesity and Metabolic Research

0:00 2:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Applied Clinical Trials?

This episode is 2 minutes long.

When was this Applied Clinical Trials episode published?

This episode was published on November 7, 2025.

Can I download this Applied Clinical Trials episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!